Population Pharmacokinetics of Cefazolin in Serum and Tissue for Patients with Complicated Skin and Soft Tissue Infections (cSSTI)

Infectious Diseases and Therapy

Volumn 3, Issue 2, 2014, Pages 269-279

  So, Wonhee ^a   Kuti, Joseph L ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

Cefazolin; cSSTI; Diabetic wound; Microdialysis; Tissue pharmacokinetics

Indexed keywords

CEFAZOLIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; COMPUTER SIMULATION; DRUG PENETRATION; EXPERIMENTAL MODEL; FEMALE; HUMAN; INTERSTITIAL FLUID; MALE; MICRODIALYSIS; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; QUANTITATIVE ASSAY; SKIN INFECTION; SOFT TISSUE INFECTION; VERY ELDERLY;

ENTEROBACTERIACEAE; STAPHYLOCOCCUS AUREUS;

EID: 84977079271     PISSN: 21938229     EISSN: 21936382     Source Type: Journal    
DOI: 10.1007/s40121-014-0049-3     Document Type: Article

References (26)

1. Zervos MJ, Freeman K, Vo L, et al. Epidemiology and outcomes of complicated skin and soft tissue infections in hospitalized patients. J Clin Microbiol. 2012;50(2):238–45.
2. Garau J, Ostermann H, Medina J, et al. Current management of patients hospitalized with complicated skin and soft tissue infections across Europe (2010–2011): assessment of clinical practice patterns and real-life effectiveness of antibiotics from the REACH study. Clin Microbiol Infect. 2013;19(9):E377–85.
3. Cefazolin package insert. http://www.sagentpharma.com/Products/Cefazolin/Catalog/Cefazolin_PI1.pdf?PHPSESSID=22da06f6533ba6c3576d3c28d8b41882. Accessed June 16, 2014.
4. Housman ST, Sutherland CA, Nicolau DP. Pharmacodynamic profile of commonly utilisedparenteral therapies against methicillin-susceptible/resistant Staphylococcus aureus from US hospitals. (Abstract No. eP178). The 24th European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain, May 2014.
5. Paterson DL, Ko WC, Von Gottberg A, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol. 2001;39(6):2206–12.
6. Clinical and Laboratory Standards Institute. 7th ed. M100 S20–S23. CLSI, Wayne, PA, USA; 2012.
7. Turnidge JD. On behalf of the subcommittee on antimicrobial susceptibility testing of the Clinical and Laboratory Standards Institute. Cefazolin and Enterobacteriaceae: rationale for revised susceptibility testing breakpoints. Clin Infect Dis. 2011;52(7):917–24.
8. Bhalodi AA, Housman ST, Shepard A, Nugent J, Nicolau DP. Tissue pharmacokinetics of cefazolin in patients with lower limb infections. Antimicrob Agents Chemother. 2013;57(11):5679–83.
9. Stahle L, Arner P, Ungerstedt U. Drug distribution studies with microdialysis III: extracellular concentration of caffeine in adipose tissue in man. Life Sci. 1991;49(24):1853–8.
10. Lipsky BA, Berendt AR, Cornia PB, et al. 2012 Infectious diseases society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2012;54(12):132–73.
11. Chaurasia CS, Muller M, Bashaw ED, et al. AAPS-FDA workshop white paper: microdialysis principles, application, and regulatory perspectives. J Clin Pharmacol. 2007;47(5):589–603.
12. Dudley MN, Nightingale CH, Drezner AD, Low HB, Wuintiliani R. Comparative penetration of cefonicid and cefazolin into the atrial appendage and pericardial fluid of patients undergoing open-heart surgery. Antimicrob Agents Chemother. 1984;26(3):347–50.
13. Neely MN, van Guilder MG, Yamada WM, Schumitzky A, Jelliffe RW. Accurate detection of outliers and subpopulations with Pmetrics, a non-parametric and parametric pharmacometric modeling and simulation package for R. Ther Drug Monit. 2012;34(4):467–76.
14. Yamaoka K, Nakagawa T, Uno T. Application of Akaike’s information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm. 1978;6(2):165–75.
15. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.
16. Winter MA, Guhr KN, Berg GM. Impact of various body weights and serum creatinine concentrations on the bias and accuracy of the Cockcroft–Gault equation. Pharmacotherapy. 2012;32(7):604–12.
17. van Kralingen S, Taks M, Diepstraten J, et al. Pharmacokinetics and protein binding of cefazolin in morbidly obese patients. Eur J Clin Pharmacol. 2011;67(10):985–92.
18. Douglas A, Udy AA, Wallis SC, et al. Plasma and tissue pharmacokinetics of cefazolin in patients undergoing elective and semi-elective abdominal aortic aneurysm open repair surgery. Antimicrob Agents Chemother. 2011;55(11):5238–42.
19. Brill MJE, Houwink API, Schmidt S, et al. Reduced subcutaneous tissue distribution of cefazolin in morbidly obese versus non-obese patients determined using clinical microdialysis. J Antimicrob Chemother. 2014;69(3):715–23.
20. Muller M, dela Pena A, Derendorf H. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue. Antimicrob Agents Chemother. 2004;48(5):1441–53.
21. MacGowan AP, Bowker KE. Continuous infusion of beta-lactam antibiotics. Clin Pharmacokinet. 1998;35(5):391–402.
22. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26(1):1–12.
23. Keel RA, Crandon JL, Nicolau DP. Efficacy of human simulated exposures of ceftaroline administered at 600 milligrams every 12 hours against phenotypically diverse Staphylococcus aureus isolates. Antimicrob Agents Chemother. 2011;55(9):4028–32.
24. Andes D, Craig WA. Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target. Antimicrob Agents Chemother. 2006;50(4):1376–83.
25. Drusano GL. Antimicrobial pharmacodynamics: critical interactions of ‘Bug and Drug’. Nat Rev Microbiol. 2004;2(4):289–300.
26. Craig WA, Andes DR. In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models. Antimicrob Agents Chemother. 2008;52(10):3492–6.